Peter M Voorhees

1 month ago | nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more

AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.

Jul 7, 2024 | nature.com | Ajai Chari |Jonathan Kaufman |Jacob P. Laubach |Brandi N. Reeves |Luciano Costa |Sarah A Holstein | +4 more

AbstractThe randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]).

Jan 25, 2024 | targetedonc.com | Peter M Voorhees

In this Precision Medicine Perspectives series, “Evaluating Treatment Outcomes in Newly Diagnosed Multiple Myeloma,” Peter Voorhees, MD, at the Levine Cancer Institute in Charlotte, NC, outlines the therapeutic landscape of newly diagnosed multiple myeloma and explores how recent data will shape treatment paradigms. Targeted Oncology™: Regarding treatment selection in newly diagnosed multiple myeloma, what factors guide your selection for induction maintenance and consolidation therapy?

Dec 21, 2023 | targetedonc.com | Peter M Voorhees

Current and Emerging Standard of Care in NDMMExpert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.

Oct 18, 2023 | newsbreak.com | Peter M Voorhees

This site uses various technologies, including third-party cookies, pixels, and codes, to personalize our website functionalities, measure website usage and performance and provide targeting advertising. Information about your site visit may be stored or shared with third parties as identified in our Privacy Policy. By continuing to use this website you consent to our Privacy Policy and Terms of Use.